Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Somaxon Pharmaceuticals has obtained $245,000 non-taxable grant under the Qualifying Therapeutic Discovery Project (QTDP) program related to Silenor (doxepin).
Subscribe to our email newsletter
Silenor is approved for use in people with chronic (long-term) or transient (short-term) insomnia characterised by difficulty with sleep maintenance.
According to Somaxon, Silenor can be used for as long as recommended by the treating physician, and is approved for use in adults and in the elderly.
Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialisation of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.